These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16314657)

  • 61. Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer.
    Anderson WF; Rosenberg PS; Katki HA
    J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24777110
    [No Abstract]   [Full Text] [Related]  

  • 62. Personalized medicine for breast cancer: it is a new day!
    Russell CA
    Am J Surg; 2014 Mar; 207(3):321-5. PubMed ID: 24581758
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Lesson learned from high-dose chemotherapy for high-risk breast cancer (What you see is what you mean).
    Colleoni M; Rotmensz N; Martinelli G; Gelber R; Coates A; Goldhirsch A
    Ann Oncol; 2004 Feb; 15(2):355-6. PubMed ID: 14760134
    [No Abstract]   [Full Text] [Related]  

  • 64. Two birds with one stone: octreotide treatment for acromegaly and breast cancer.
    Chae YK; Hu MI; Katz RL; Chavez-MacGregor M; Haluska P; Meric-Bernstam F; Gonzalez-Angulo AM; Melhem-Bertrandt A
    J Clin Oncol; 2013 Aug; 31(23):e398-400. PubMed ID: 23796991
    [No Abstract]   [Full Text] [Related]  

  • 65. Hormone receptors in breast cancer.
    Appelbaum J
    Br Med J; 1978 Oct; 2(6145):1161-2. PubMed ID: 709280
    [No Abstract]   [Full Text] [Related]  

  • 66. Role of endocrine therapy in weak estrogen/progesterone receptor expression in HER2 negative breast cancer.
    Altundag K
    Eur J Surg Oncol; 2018 Apr; 44(4):539. PubMed ID: 29426782
    [No Abstract]   [Full Text] [Related]  

  • 67. An unmet need: tailoring extended adjuvant endocrine therapy.
    Bianchini G; Gianni L
    Br J Cancer; 2013 Dec; 109(12):2951-3. PubMed ID: 24253504
    [No Abstract]   [Full Text] [Related]  

  • 68. The round ligament: a target organ for steroid hormones.
    Smith P; Heimer G; Norgren A; Ulmsten U
    Gynecol Endocrinol; 1993 Jun; 7(2):97-100. PubMed ID: 8213233
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Fluctuation of intratumor biological variables as a function of menstrual timing of surgery for breast cancer in premenopausal patients.
    Coradini D; Veneroni S; Pellizzaro C; Daidone MG
    Ann Oncol; 2003 Jun; 14(6):962-4. PubMed ID: 12796038
    [No Abstract]   [Full Text] [Related]  

  • 70. 2013 update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers.
    Lambein K; Van Bockstal M; Denys H; Libbrecht L
    J Clin Oncol; 2014 Jun; 32(17):1856-7. PubMed ID: 24778399
    [No Abstract]   [Full Text] [Related]  

  • 71. Evaluation of nonlinear optical differences between breast cancer cell lines SK-BR-3 and MCF-7; an in vitro study.
    Ghader A; Ardakani AA; Ghaznavi H; Shakeri-Zadeh A; Minaei SE; Mohajer S; Ara MHM
    Photodiagnosis Photodyn Ther; 2018 Sep; 23():171-175. PubMed ID: 29933083
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry.
    Siddiqui S; Rimm DL
    Breast Cancer Res; 2010; 12(6):113. PubMed ID: 21176180
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hormones and gallbladder cancer in women.
    Barreto SG; Haga H; Shukla PJ
    Indian J Gastroenterol; 2009; 28(4):126-30. PubMed ID: 19937419
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Flashback Foreword: Estrogen Receptor by Immunohistochemistry in Breast Cancer.
    Ganz PA
    J Clin Oncol; 2023 Mar; 41(7):1329-1330. PubMed ID: 36827741
    [No Abstract]   [Full Text] [Related]  

  • 75. Reply to R. Bhargava et al and K. Lambein et al.
    Wolff AC; Hammond ME; Hicks DG; Dowsett M; Hayes DF; McShane LM
    J Clin Oncol; 2014 Jun; 32(17):1857-9. PubMed ID: 24778389
    [No Abstract]   [Full Text] [Related]  

  • 76. Breast cancer subtypes in transplant patients: Does it really matter?
    Altundag K
    Clin Imaging; 2021 Oct; 78():93. PubMed ID: 33773448
    [No Abstract]   [Full Text] [Related]  

  • 77. Biostatistics and tumor marker studies in breast cancer: design, analysis and interpretation issues.
    Biganzoli E; Boracchi P; Marubini E
    Int J Biol Markers; 2003; 18(1):40-8. PubMed ID: 12699062
    [No Abstract]   [Full Text] [Related]  

  • 78. Reply to Y.Yamamoto et al.
    Prat A; Martin M; Nielsen TO; Perou CM
    J Clin Oncol; 2013 Jul; 31(19):2517-8. PubMed ID: 23967491
    [No Abstract]   [Full Text] [Related]  

  • 79. Comment on 'Renewed interest in the progesterone receptor in breast cancer'.
    Simone G; Diotaiuti S; Digennaro M; Sambiasi D; De Summa S; Tommasi S; Altieri R; Mangia A; Dantona C; Paradiso A
    Br J Cancer; 2017 Jul; 117(2):e1. PubMed ID: 28399113
    [No Abstract]   [Full Text] [Related]  

  • 80. Biomarkers, animal models key in progress of chemoprevention.
    Miller M
    J Natl Cancer Inst; 2001 Jul; 93(13):975-6. PubMed ID: 11438560
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.